Gene expression markers of Tumor Infiltrating Leukocytes
Patrick Danaher,Sarah Warren,Lucas Dennis,Leonard D’Amico,Andrew White,Mary L. Disis,Melissa A. Geller,Kunle Odunsi,Joseph Beechem,Steven P. Fling
DOI: https://doi.org/10.1186/s40425-017-0215-8
IF: 12.469
2017-02-21
Journal for ImmunoTherapy of Cancer
Abstract:<span><i><b>Aim:</b></i> To assess relative expression (RE) levels of CAF-, TAM-specific, immune defense-associated genes in prostate tumors and to show correlation of RE with clinical, pathological and molecular characteristics, with the aim to define clinically significant specific alterations in a gene expression pattern. <i><b>Methods:</b></i> RE of 23 genes was analyzed by a quantitative polymerase chain reaction in 37 freshly frozen samples of prostate cancer tissues of a different Gleason score (GS) and at various tumor stages, compared with RE in 37 paired conventionally normal prostate tissue (CNT) samples and 20 samples of prostate adenomas. <i><b>Results:</b></i> Differences in RE were shown for 11 genes out of 23 studied, when tumor samples were compared with corresponding CNTs. 7 genes, namely <i><b>ACTA2, CXCL14, CTGF, THY1, FAP, CD163, CCL17</b></i> were upregulated in tumors. 4 genes, namely <i><b>CCR4, NOS2A, MSMB, IL1R1</b></i> were downregulated in tumors. 14 genes demonstrated different RE in TNA at different stages: <i><b>CXCL12, CXCL14, CTGF, FAP, HIF1A, THY1, CCL17, CCL22, CCR4, CD68, CD163, NOS2A, CTLA4, IL1R1.</b></i> RE changes of 9 genes — <i><b>CXCL12, CXCL14, HIF1A, CCR4, CCL17, NOS2A, CTLA4, IL1R1, IL2RA</b></i> — were found in tumors with different GS. Moreover, 9 genes showed differences in RE in TNA, dependently on the presence or absence of the TMPRSS2/ERG fusion and 7 genes showed differences in RE of groups with differential <i><b>PTEN</b></i> expression. Significant correlations were calculated between RE of 9 genes in adenocarcinomas and the stage, and GS; also, between RE of 2 genes and the fusion presence; and between RE of 4 genes and <i><b>PTEN</b></i> expression. <i><b>Conclusions:</b></i> Several gene expression patterns were identified that correlated with the GS, stage and molecular characteristics of tumors, i.e. presence of the TMPRSS2/ERG fusion and alterations in <i><b>PTEN</b></i> expression. These expression patterns can be used for molecular profiling of prostate tumors, with the aim to develop personalized medicine approaches. However, the proposed profiling requires a more detailed analysis and a larger cohort of patients with prostate tumor.</span>
oncology,immunology